Shanghai Resurrection Stone Pharmaceutical Technology

Shanghai Resurrection Stone Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the field of targeted protein degradation (TPD). The company focuses on the discovery and development of novel molecular glues and PROTACs to address undruggable targets in oncology and immunology. Leveraging its proprietary discovery platform, Resurrection Stone identifies small molecules that recruit E3 ligases to induce the degradation of disease-causing proteins. Its lead program, FS-001, is a potent GSPT1 degrader currently undergoing Phase 1 clinical trials for advanced malignancies. The firm is led by a team of experienced drug discovery experts and is supported by top-tier investors such as Lilly Asia Ventures and IDG Capital. The company aims to provide innovative therapeutic solutions for patients with limited treatment options.